salmeterol
UkraineDrugs containing this active substance
-
The drug is intended for the regular treatment of bronchial asthma in patients who require combination therapy (a combination of two types of active substances). It is used if standard therapy does not provide adequate symptom control or if the patient is already benefiting from combination treatment with different drugs.
Form: aerosol, metered dose for inhalation
Active substance Dosage salmeterol 25 mcg per dose fluticasone 50 mcg/dose ATC: R03AK06
Manufacturer: Glenmark Pharmaceuticals Ltd.
-
The drug is intended for the regular treatment of bronchial asthma in patients who require combination therapy (a combination of two types of active substances). It is used if standard therapy does not provide sufficient symptom control or if the patient is already benefiting from combination treatment using different drugs in separate inhalers.
Form: aerosol, metered dose for inhalation
Active substance Dosage salmeterol 25 mcg per dose fluticasone 125 mcg/dose ATC: R03AK06
Manufacturer: Glenmark Pharmaceuticals Ltd.
-
The drug is intended for the regular treatment of bronchial asthma in patients who require combination therapy (a combination of two types of active substances). It is used if standard therapy does not provide sufficient symptom control, or as a maintenance treatment if asthma has already been successfully controlled with other combination drugs.
Form: aerosol, metered dose for inhalation
Active substance Dosage salmeterol 25 mcg per dose fluticasone propionate 250 mcg/dose ATC: R03AK06
Manufacturer: Glenmark Pharmaceuticals Ltd.
-
The drug is used for the regular treatment of bronchial asthma (if other methods do not provide sufficient control) and for maintenance therapy in chronic obstructive pulmonary disease (COPD).
Form: powder, inhalation, metered
Active substance Dosage salmeterol 50 mcg fluticasone propionate 100 mcg ATC: R03AK06
Manufacturer: Glaxo Wellcome Production
-
The drug is used for the regular treatment of bronchial asthma (if other methods do not provide sufficient control) and for maintenance therapy in chronic obstructive pulmonary disease (COPD).
Form: powder, inhalation, metered
Active substance Dosage salmeterol 50 mcg/dose fluticasone 250 mcg/dose ATC: R03AK06
Manufacturer: Glaxo Wellcome Production
-
The drug is used for the regular treatment of bronchial asthma and maintenance therapy for chronic obstructive pulmonary disease (COPD).
Form: powder, inhalation, metered
Active substance Dosage salmeterol 50 mcg/dose fluticasone 500 mcg/dose ATC: R03AK06
Manufacturer: Glaxo Wellcome Production
-
The drug is intended for the regular treatment of bronchial asthma in patients who require combination therapy (a combination of a long-acting bronchodilator and an inhaled corticosteroid).
Form: aerosol, metered for inhalation
Active substance Dosage salmeterol 25 mcg per dose fluticasone 50 mcg/dose ATC: R03AK06
Manufacturer: Glaxo Wellcome Production
-
The drug is intended for the regular treatment of bronchial asthma in patients who require combination therapy (a combination of a long-acting bronchodilator and an inhaled corticosteroid).
Form: aerosol, metered for inhalation
Active substance Dosage salmeterol 25 mcg fluticasone 250 mcg ATC: R03AK06
Manufacturer: Glaxo Wellcome Production
-
The drug is intended for the regular treatment of bronchial asthma in patients who require combination therapy (a combination of a long-acting bronchodilator and an inhaled corticosteroid).
Form: aerosol, metered for inhalation
Active substance Dosage salmeterol 25 mcg fluticasone propionate 125 mcg ATC: R03AK06
Manufacturer: Glaxo Wellcome Production
-
The drug is used for regular add-on treatment of asthma (including nocturnal attacks), for the treatment of chronic obstructive pulmonary disease (COPD), and for the prevention of exercise-induced asthma attacks.
Form: inhalation, suspension under pressure
Active substance Dosage salmeterol 25 mcg per dose ATC: R03AC12
Manufacturer: Cipla Ltd. (Unit II)
-
The drug is intended for the regular treatment of bronchial asthma in patients who require combination therapy (a combination of long-acting active substances and corticosteroids).
Form: aerosol, metered dose for inhalation
Active substance Dosage salmeterol 25 mcg fluticasone 125 mcg ATC: R03AK06
Manufacturer: Cipla Ltd. (Unit II)
-
The drug is intended for the regular treatment of bronchial asthma in patients who require combination therapy with long-acting β2-adrenoceptor agonists and inhaled corticosteroids.
Form: aerosol, metered dose for inhalation
Active substance Dosage salmeterol 25 mcg fluticasone 250 mcg ATC: R03AK06
Manufacturer: Cipla Ltd. (Unit II)
-
The drug is intended for the regular treatment of bronchial asthma in patients who require combination therapy with long-acting β2-adrenoceptor agonists and inhaled corticosteroids.
Form: aerosol, metered dose for inhalation
Active substance Dosage salmeterol 25 mcg fluticasone 50 mcg ATC: R03AK06
Manufacturer: Cipla Ltd. (Unit II)